Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

While there are no studies documenting the number of physicians taking GLP-1s, a number of physicians told the Times that they've noticed many colleagues growing thinner and sharing similar eating ...

The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded ...

GLP1RA mimic the GLP-1 hormone in the body that helps control insulin and blood glucose levels and promotes feelings of satiety. GLP-1 binds to GLP1R on cells in the brain and pancreas.

Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss drugs, but the jury's out on w ...

Sure, who wouldn’t want to lose a few pounds? But what’s really driving Hollywood’s latest trend is the drug’s seemingly miraculous side benefits ...

Inc. (NYSE American: PTN), a biopharmaceutical firm with a market capitalization of $23.22 million, has announced a new funding round through a registered direct offering and a concurrent private ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

Direct-to-store model (delivering drugs directly to each retailer’s stores) of distributors are increasingly becoming more popular among retailers (represents 93% of sales in 2017, up from 74% in 2007 ...

Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...